IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., *et al.*,[1] Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered) **Hearing Date: *Only if objections are filed*** **Obj. Deadline: November 24, 2026 at 4:00 p.m. (ET)**

SUMMARY OF NINTH MONTHLY FEE APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS, FOR ALLOWANCE OF COMPENSATION AND OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Name of Applicant:	Dundon Advisers LLC
Authorized to provide professional services to:	Official Committee of Unsecured Creditors of Apple Tree Life Sciences, Inc. *et al.*
Date of retention:	February 25, 2026, effective as of January 23, 2026
Period for which compensation and reimbursement is sought:	October 1, 2026 through October 31, 2026
Amount of compensation sought as actual, reasonable and necessary:	$214,624.80 (80% of $268,281.00)
Amount of expense reimbursement sought as actual, reasonable and necessary:	$0.00
This is a:	_X_ monthly ___ interim ___ final application
Prior Monthly Applications:	

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

2512177261110000000000005

Monthly Fee Application Filing Date & Docket No.	Period Covered	Total Fees Requested	Total Expenses Requested	CNO Filing Date & Docket No.	Amount of Fees Authorized to be Paid	Amount of Expenses Authorized to be Paid
3/11/2026 [D.I. 462]	January 23, 2026 – February 28, 2026	$183,255.00	$0.00	3/26/2026 [D.I. 482]	$183,255.00[2]	$0.00
4/13/2026 [D.I. 534]	March 1, 2026 – March 31, 2026	$29,196.00	$0.00	4/28/2026 [D.I. 606]	$29,196.00[2]	$0.00
5/13/2026 [D.I. 661]	April 1, 2026 – April 30, 2026	$54,596.00	$0.00	5/29/2026 [D.I. 723]	$43,676.80[3]	$0.00
6/11/2026 [D.I. 783]	May 1, 2026 – May 31, 2026	137,694.00	$0.00	6/26/2026 [D.I. 842]	$110,155.20[3]	$0.00
7/14/2026 [D.I. 929]	June 1, 2026 – June 30, 2026	$120,758.00	$0.00	8/5/2026 [D.I. 1026]	$96,606.40[3]	$0.00
8/11/2026 [D.I. 1038]	July 1, 2026 – July 31, 2026	$231,523.00	$0.00	8/26/2026 [D.I. 1086]	$185,218.40	$0.00
9/10/2026 [D.I. 1127]	August 1, 2026 – August 31, 2026	$114,596.00	$0.00	9/25/2026 [D.I. 1169]	$91,676.80	$0.00
10/12/206 [D.I. 1207]	September 1, 2026 – September 30, 2026	$102,558.00	$0.00	10/27/2026 [D.I. 1267]	$82,046.40	$0.00
Total		**$974,176.00**	**$0.00**		**$821,831.00**[23]	**$0.00**

[2] As set forth in the Debtors' Omnibus Order Awarding Interim Fee Applications [Docket No. 1083], Dundon Advisers LLC agreed to a voluntary reduction of $4,930.00. The amount shown in the chart is prior to any agreed upon reduction.

[3] As set forth in the Debtors' proposed Omnibus Order Awarding Interim Fee Applications [Docket No. 1264], Dundon Advisers LLC agreed to a voluntary reduction of $5,443.20. The amount shown in the chart is prior to any agreed upon reduction.

APPLE TREE LIFE SCIENCES, INC., *ET AL.*

SUMMARY OF BILLING BY PROFESSIONAL
OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Professional	Title	Hourly Rate	Billable Time	Billable Amount
Joshua Nahas	Managing Director	$1,120.00	113.00	$126,560.00
Gary Lipson	Senior Advisor	$1,120.00	7.50	$8,400.00
Michael Whalen	Director	$865.00	1.40	$1,211.00
Christopher Podesfinski	Associate Director	$750.00	133.90	$100,425.00
Chris Kazantzis	Senior Associate	$550.00	25.70	$14,135.00
Brodie Galfus	Associate	$390.00	45.00	$17,550.00
Total			**326.50**	**$268,281.00**

Blended Rate: $821.69

APPLE TREE LIFE SCIENCES INC., *ET AL.*

SUMMARY OF COMPENSATION BY PROJECT CATEGORY
OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Project Category	Billable Time	Billable Amount
Sales Process	120.60	$104,101.00
Business Analysis	124.00	$100,679.00
Claims Analysis	34.60	$28,921.00
Committee Member/Professional Meetings & Communications	18.70	$15,549.00
Case Administration	12.10	$5,731.00
Retention and Fee Applications	5.30	$4,123.00
DIP, Exit and Other Financing	3.50	$2,625.00
Hearing, Mediation and Arbitration Preparation	2.80	$2,322.00
Other Professionals' Retention and Fee Applications	2.70	$2,136.00
Investigations	2.20	$2,094.00
Total	**326.50**	**$268,281.00**

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., *et al*.,[1] Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered) **Hearing Date: *Only if objections are filed*** **Obj. Deadline: November 10, 2026 at 4:00 p.m. (ET)**

NINTH MONTHLY FEE APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Dundon Advisers LLC (the "Applicant" or "Dundon"), financial advisor to the Official Committee of Unsecured Creditors (the "Committee") of Apple Tree Life Sciences, Inc. and the above-captioned debtors and debtors in possession (collectively, the "Debtors") in these chapter 11 cases (the "Chapter 11 Cases"), hereby applies (the "Application"), pursuant to (i) sections 330 and 331 of title 11 of the United States Code, 11 U.S.C. §§ 101-1532 (the "Bankruptcy Code"), (ii) Rule 2016 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), (iii) Rule 2016-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the "Local Rules"), and (iv) the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief*

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

[Docket No. 181] (the "Interim Compensation Order"),[2] for allowance of compensation for services rendered and reimbursement of expenses for the period from October 1, 2026 through October 31, 2026 (the "Application Period"), and respectfully represents as follows:

Jurisdiction and Venue

1. The Court has jurisdiction to consider the Application pursuant to 28 U.S.C. §1334. This is a core proceeding pursuant to 28 U.S.C. § 157(b). Venue is proper in this District pursuant to 28 U.S.C. §§ 1408 and 1409.

2. Pursuant to Local Rule 9013-1(f), the Committee consents to entry of a final judgment or order with respect to this Application if it is determined that the Court would lack Article III jurisdiction to enter such final order or judgment absent consent of the parties.

3. The statutory predicates for the relief sought herein are sections 330 and 331 of the Bankruptcy Code. Such relief also is warranted under Bankruptcy Rule 2016, Local Rule 2016-1 and the Interim Compensation Order.

Background

A. The Chapter 11 Cases

4. Commencing on December 9, 2025 (the "Initial Petition Date") and on certain dates thereafter (collectively with the Initial Petition Date, the "Petition Dates"), each of the Debtors filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code. These Chapter 11 Cases are being jointly administered for procedural purposes only pursuant to Bankruptcy Rule 1015(b). The Debtors are operating their business and managing their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

[2] Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Interim Compensation Order.

5. On January 20, 2026, the Office of the United States Trustee for Region 3 (the "U.S. Trustee") filed a notice appointing a three-member Committee consisting of: (i) Fujifilm Cellular Dynamics Inc.; (ii) Global Project Partners, LLC; and (iii) Baylor College of Medicine. *See* Docket No. 194. Baylor College of Medicine serves as the chairperson of the Committee.

B. The Retention of Dundon

6. On February 4, 2026, the Committee applied to the Court for an order authorizing the retention and employment of Dundon as financial advisor to the Committee, effective as of January 23, 2026. *See* Docket No. 267.

7. On February 25, 2026, the Court entered the *Order Pursuant to 11 U.S.C. §§ 328(a) and 1103 Authorizing and Approving the Retention and Employment of Dundon Advisers LLC as Financial Advisor to the Official Committee of Unsecured Creditors Effective as of January 23, 2026* [Docket No. 411], authorizing the retention and employment of Dundon as financial advisor to the Committee.

C. The Interim Compensation Order

8. The Interim Compensation Order sets forth the procedures for interim compensation and reimbursement of expenses in these Chapter 11 Cases. Specifically, the Interim Compensation Order provides that on or after the tenth day of each month following the month for which compensation is sought, each Professional seeking compensation may file an application (each, a "Monthly Fee Statement") for interim allowance of compensation for services rendered and reimbursement of expenses incurred during the preceding month and serve such Monthly Fee Statement on the Notice Parties. *See* Interim Compensation Order ¶ 2(a). Provided that there are no objections to the Monthly Fee Statement filed within fourteen (14) days after service of a Monthly Fee Statement, a Professional may file a certificate of no

objection with the Court with respect to the unopposed portion of the compensation and expenses requested in its Monthly Fee Statement, after which the Debtors are authorized to pay such Professional eighty percent (80%) of the fees and one-hundred percent (100%) of the expenses requested in such Monthly Fee Statement. *Id.* ¶ 2(b).

Relief Requested

9. Pursuant to the Interim Compensation Order and section 331 of the Bankruptcy Code, Dundon is seeking compensation in the amount of $214,624.80, which is equal to eighty percent (80%) of the $268,281.00 in fees for professional services rendered by Dundon during the Application Period. This amount is derived solely from the applicable hourly billing rates of Dundon professionals who rendered such services to the Committee.

D. Compensation Requested

10. Attached hereto as **Exhibit A** is a detailed itemization, by project category, of all services performed by Dundon with respect to the Chapter 11 Cases during the Application Period. This detailed itemization complies with Local Rule 2016-1(d) in that each time entry contains a separate time allotment, a description of the type of activity and the subject matter of the activity, all time is billed in increments of one-tenth of an hour, time entries are presented chronologically in categories and all meetings or hearings are individually identified. *See* DEL. BANKR. L.R. 2016-1(d).

11. The professionals who rendered services related to each category are identified in **Exhibit A**, along with the number of hours for each individual and the total compensation sought for each category.

Valuation of Services

12. Dundon professionals have expended a total of 326.50 hours in connection with this matter during the Application Period.

13. The amount of time spent by each of the professionals providing services to the Committee for the Application Period is set forth in **Exhibit A**. The rates are Dundon's normal hourly rates of compensation for work of this character. The reasonable value of the services rendered by Dundon for the Application Period as financial advisor to the Committee in these Chapter 11 Cases is $268,281.00.

14. Dundon believes that the time entries included in **Exhibit A** comply with the requirements of Local Rule 2016-1.

15. Dundon's itemized time records for professionals performing services for the Committee during the Application Period are attached hereto as **Exhibit B**. Every effort has been made by Dundon to categorize daily time entries in accordance with the correct project category. However, in some instances, services overlap between project categories. Thus, some services may appear under more than one category, although in no instance is a specific time entry recorded more than once.

16. Although every effort has been made to include all fees and expenses incurred in the Application Period, some fees and expenses might not be included in this Monthly Fee Statement due to delays caused by accounting and processing during the Application Period. Dundon reserves the right to make further applications to the Court for allowance of such fees and expenses not included herein. Subsequent Monthly Fee Statements will be filed in accordance with the Bankruptcy Code, the Bankruptcy Rules, and the Interim Compensation Order.

17. In accordance with the factors enumerated in section 330 of the Bankruptcy Code, the amount requested is fair and reasonable given (a) the complexity of these Chapter 11 Cases,

(b) the time expended, (c) the nature and extent of the services rendered, (d) the value of such services, and (e) the costs of comparable services other than in a case under this title.

No Prior Request

18. No prior request for the relief sought in the Application has been made to this or any other court.

Certificate of Compliance and Waiver

19. The undersigned representative of Dundon certifies that he has reviewed the requirements of Local Rule 2016-1, and that the Application substantially complies with that Local Rule. To the extent that the Application does not comply in all respects with the requirements of Local Rule 2016-1, Dundon believes that such deviations are not material and respectfully requests that any such requirements be waived.

Notice

20. Dundon will provide notice of this Application by electronic mail to: (i) counsel to the Debtors; (ii) the U.S. Trustee; and (iii) those persons who have formally appeared in these Chapter 11 Cases and requested service pursuant to Bankruptcy Rule 2002. In light of the nature of the relief requested, Dundon submits that no other or further notice of the Application is required.

Conclusion

WHEREFORE, Dundon respectfully requests (a) allowance of compensation for professional services rendered to the Committee during the Application Period in the amount of $214,624.80 (80% of $268,281.00) and reimbursement for actual and necessary expenses incurred during the Application Period in the amount of $0.00; (b) payment by the Debtors of the foregoing amounts; and (c) such other and further relief as the Court deems just and proper.

Dated: November 10, 2026
New York, New York

DUNDON ADVISERS LLC

/s/ Joshua Nahas

Joshua Nahas
565 Fifth Avenue, 16th Floor
New York, New York 10017
Telephone: (212) 859-2000
Email: jn@dundon.com

Financial Advisor to the Official Committee of Unsecured Creditors of Apple Tree Life Sciences, Inc. et al.

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., *et al.*,[1] Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered) **Hearing Date: *Only if objections are filed*** **Obj. Deadline: November 24, 2026 at 4:00 p.m. (ET)**

NOTICE OF NINTH MONTHLY FEE APPLICATION OF DUNDON ADVISERS LLC, FINANCIAL ADVISOR TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD FROM OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

PLEASE TAKE NOTICE that on November 10, 2026, Dundon Advisers LLC filed with the United States Bankruptcy Court for the District of Delaware (the "Court") the *Ninth Monthly Fee Application of Dundon Advisers LLC, Financial Advisor to the Official Committee of Unsecured Creditors, for Allowance of Compensation and Reimbursement of Expenses for the Period from October 1, 2026 Through October 31, 2026* (the "Application"), which seeks approval of fees for professional services rendered to the Committee in the amount of $214,624.80 (80% of $268,281.00), together with reimbursement of expenses in the amount of $0.00.

PLEASE TAKE FURTHER NOTICE that objections, if any, to the Application are required to be filed with the Clerk of the United States Bankruptcy Court for the District of Delaware, 824 North Market Street, 3rd Floor, Wilmington, Delaware 19801, and served on the following, so as to be **received no later than 4:00 p.m. (ET) on November 24, 2026 (the "Objection Deadline")**: (i) co-counsel to the Debtors, (a) Quinn Emanuel Urquhart & Sullivan, LLP, 295 5th Avenue, 9th Floor, New York, New York 10016 (Attn: Andrew M. Berdon (andrewberdon@quinnemanuel.com) and Patricia B. Tomasco (pattytomasco@quinnemanuel.com)) and Quinn Emanuel Urquhart & Sullivan, LLP, 865 S. Figueroa Street, 10th Floor, Los Angeles, California 90017 (Attn: Eric D. Winston (ericwinston@quinnemanuel.com)); (b) Potter Anderson & Corroon LLP, 1313 N. Market Street, 6th Floor, Wilmington, Delaware 19801-6108 (Attn: L. Katherine Good (kgood@potteranderson.com) and Brett M. Haywood (bhaywood@potteranderson.com)); and (c) Murphy & King, P.C., 28 State Street, Suite 3101, Boston, Massachusetts 02109 (Attn: Harold B. Murphy (hmurphy@murphyking.com) and Andrew G. Lizotte (alizotte@murphyking.com)); (ii) co-counsel to the Fund Debtor, (a) DLA Piper LLP (US), 1201 North Market Street, Suite 2100,

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

Wilmington, Delaware, 19801 (Attn: R Craig Martin (craig.martin@us.dlapiper.com); and (b) Eldridge Legal LLP, Suite F, Third Floor, Century Yard, Cricket Square, PO Box 30112, KY1-1201 (Attn: James Eldridge (james.eldridge@eldridge legal.com)); (iii) the U.S. Trustee, J. Caleb Boggs Federal Building, 844 King Street, Suite 2207, Lockbox 35, Wilmington, Delaware 19801 (Attn: Hannah McCollum (hannah.mccollum@usdoj.gov) and Megan Seliber (megan.seliber@usdoj.gov)); (iv) counsel to the Official Committee of Unsecured Creditors, Cole Schotz P.C., 500 Delaware Avenue, Suite 600, Wilmington, DE 19801, Attn: Justin Alberto (jalberto@coleschotz.com) and Patrick Reilley (preilley@coleschotz.com); and (v) the Court Appointed Fee Examiner, Rucki Fee Review, LLC, 1111 Windon Drive, Wilmington Delaware 19803 (Attn: Justin Rucki (justinrucki@ruckifeereview.com)).

PLEASE TAKE FURTHER NOTICE that pursuant to the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief* [Docket No. 181], if no objections are filed and served in accordance with the above procedures, the Debtors will be authorized to pay 80% of the requested fees and 100% of the requested expenses without further order of the Court.

PLEASE TAKE FURTHER NOTICE THAT A HEARING ON THE APPLICATION WILL BE HELD ONLY IF AN OBJECTION IS TIMELY FILED, OR THE COURT DIRECTS OTHERWISE, AT A DATE AND TIME TO BE SCHEDULED BEFORE THE HONORABLE LAURIE SELBER SILVERSTEIN, UNITED STATES BANKRUPTCY JUDGE, UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE, 6TH FLOOR, COURTROOM NO. 2, 824 NORTH MARKET STREET, WILMINGTON, DELAWARE 19801.

[*Remainder of Page Intentionally Left Blank*]

Dated: November 10, 2026
Wilmington, Delaware

COLE SCHOTZ P.C.

/s/ Carol E. Thompson
Justin R. Alberto (No. 5126)
Patrick J. Reilley (No. 4451)
Jack M. Dougherty (No. 6784)
Carol E. Thompson (No. 6936)
500 Delaware Avenue, Suite 600
Wilmington, DE 19801
Telephone: (302) 652-3131
Facsimile: (302) 652-3117
Email: jalberto@coleschotz.com
preilley@coleschotz.com
jdougherty@coleschotz.com
cthompson@coleschotz.com

Counsel to the Official Committee of Unsecured Creditors of Apple Tree Life Sciences, Inc. et al.

EXHIBIT A

APPLE TREE LIFE SCIENCES, INC., *ET AL.*

SUMMARY OF COMPENSATION BY PROJECT CATEGORY
OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Project Category	Billable Time	Billable Amount
Sales Process	120.60	$104,101.00
Business Analysis	124.00	$100,679.00
Claims Analysis	34.60	$28,921.00
Committee Member/Professional Meetings & Communications	18.70	$15,549.00
Case Administration	12.10	$5,731.00
Retention and Fee Applications	5.30	$4,123.00
DIP, Exit and Other Financing	3.50	$2,625.00
Hearing, Mediation and Arbitration Preparation	2.80	$2,322.00
Other Professionals' Retention and Fee Applications	2.70	$2,136.00
Investigations	2.20	$2,094.00
Total	**326.50**	**$268,281.00**

APPLE TREE LIFE SCIENCES, INC., *ET AL.*

SUMMARY OF BILLING BY PROFESSIONAL
OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Professional	Title	Hourly Rate	Billable Time	Billable Amount
Joshua Nahas	Managing Director	$1,120.00	113.00	$126,560.00
Gary Lipson	Senior Advisor	$1,120.00	7.50	$8,400.00
Michael Whalen	Director	$865.00	1.40	$1,211.00
Christopher Podesfinski	Associate Director	$750.00	133.90	$100,425.00
Chris Kazantzis	Senior Associate	$550.00	25.70	$14,135.00
Brodie Galfus	Associate	$390.00	45.00	$17,550.00
Total			**326.50**	**$268,281.00**

Blended Rate: $821.69

EXHIBIT B

APPLE TREE LIFE SCIENCES, INC., *ET AL*

ITEMIZED TIME RECORDS
OCTOBER 1, 2026 THROUGH OCTOBER 31, 2026

Professional	Entry Date	Client	Project Category	Description	Billable Time	Billable Amt
Brodie Galfus	10/02/2026	Apple Tree Life Sciences	Case Administration	Updated data room with new files for 10/2/2026 and sent internally	0.30	$117.00
Brodie Galfus	10/02/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Deep Apple, Apertor, Marlinspike diligence questions and Nereid Overview	1.60	$624.00
Brodie Galfus	10/02/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Master Braeburn Model	1.10	$429.00
Brodie Galfus	10/06/2026	Apple Tree Life Sciences	Business Analysis	Updated and reviewed new files added to the data room on 10/6 relating to Aulos and Nine Square	0.70	$273.00
Brodie Galfus	10/07/2026	Apple Tree Life Sciences	Business Analysis	Updated and reviewed new files added to the data room relating to Red Queen's budget and overview presentation	0.90	$351.00
Brodie Galfus	10/07/2026	Apple Tree Life Sciences	Business Analysis	Created excel exhibits for July MOR	1.90	$741.00
Brodie Galfus	10/08/2026	Apple Tree Life Sciences	Case Administration	Updated data room index and reviewed new files relating to Aethon overviews, Evercrisp overviews, and Ascidian audited financials	2.40	$936.00
Brodie Galfus	10/08/2026	Apple Tree Life Sciences	Business Analysis	Created presentation for July MOR presentation	2.70	$1,053.00
Brodie Galfus	10/09/2026	Apple Tree Life Sciences	Business Analysis	Reviewed MOR presentation with C. Kazantzis	2.90	$1,131.00
Brodie Galfus	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Attended meeting with Potter / Cole Schotz regarding case updates	0.50	$195.00

Brodie Galfus	10/20/2026	Apple Tree Life Sciences	Case Administration	Updated data room index with new files	0.80	$312.00
Brodie Galfus	10/20/2026	Apple Tree Life Sciences	Case Administration	Reviewed documents relating to Deep Apple, Evercrisp, and Initial	2.90	$1,131.00
Brodie Galfus	10/22/2026	Apple Tree Life Sciences	Case Administration	Updated data room index for new documents	0.70	$273.00
Brodie Galfus	10/22/2026	Apple Tree Life Sciences	Case Administration	Reviewed new documents relating to Aulos, Galvanize, Nereid, Marengo, and Marlinspike	2.60	$1,014.00
Brodie Galfus	10/24/2026	Apple Tree Life Sciences	Sales Process	Internal call reviewing bids and sale process	2.80	$1,092.00
Brodie Galfus	10/24/2026	Apple Tree Life Sciences	Sales Process	Call with C. Kazantzis reviewing new bids and set of information received	2.60	$1,014.00
Brodie Galfus	10/24/2026	Apple Tree Life Sciences	Sales Process	Reviewed LOIs received	1.50	$585.00
Brodie Galfus	10/24/2026	Apple Tree Life Sciences	Business Analysis	Started overview of LOIs presentation	1.10	$429.00
Brodie Galfus	10/25/2026	Apple Tree Life Sciences	Business Analysis	Updated Overview of LOI presentation	1.40	$546.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Business Analysis	Updated bid overview presentation	2.90	$1,131.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal call recapping meeting with B. riley on LOIs	0.30	$117.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Business Analysis	Reviewed claims by debtor entity with C. Kazantzis and M. Whalen	1.40	$546.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Business Analysis	Finalized LOI summary with C. Kazantzis after incorporating claims by Debtor	1.60	$624.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Business Analysis	Internal call reviewing analysis of LOIs	1.80	$702.00
Brodie Galfus	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing bids	0.40	$156.00

Brodie Galfus	10/27/2026	Apple Tree Life Sciences	Business Analysis	Revised bid overview presentation for J. Nahas comments	2.40	$936.00
Brodie Galfus	10/27/2026	Apple Tree Life Sciences	Claims Analysis	Call with C. Podesfinski making updates to claims by portco charts	0.30	$117.00
Brodie Galfus	10/29/2026	Apple Tree Life Sciences	Business Analysis	Meeting with C. Podesfinski going through filed claims	0.70	$273.00
Brodie Galfus	10/29/2026	Apple Tree Life Sciences	Business Analysis	Reviewed claims analysis with supporting schedules	1.00	$390.00
Brodie Galfus	10/29/2026	Apple Tree Life Sciences	Business Analysis	Meeting with B. Riley regarding claims analysis	0.50	$195.00
Brodie Galfus	10/30/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Attended meeting with B. Riley regarding updated claims analysis	0.30	$117.00
Totals For Brodie Galfus					**45.00**	**$17,550.00**
Chris Kazantzis	10/09/2026	Apple Tree Life Sciences	Business Analysis	Reviewed MORs presentation to finalize draft with B. Galfus	2.90	$1,595.00
Chris Kazantzis	10/15/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Met with BRiley to discuss sale process updates	0.50	$275.00
Chris Kazantzis	10/15/2026	Apple Tree Life Sciences	Claims Analysis	Review organization chart and claims at each portco	1.70	$935.00
Chris Kazantzis	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Met with debtors to discuss case updates	0.50	$275.00
Chris Kazantzis	10/24/2026	Apple Tree Life Sciences	Sales Process	Internal call reviewing bids and sale process	2.80	$1,540.00
Chris Kazantzis	10/24/2026	Apple Tree Life Sciences	Sales Process	Call with B. Galfus reviewing new bids and set of information received	2.60	$1,430.00
Chris Kazantzis	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski regarding bid comparison deck	0.20	$110.00
Chris Kazantzis	10/24/2026	Apple Tree Life Sciences	Sales Process	Reviewed LOIs received and summarized missing information	0.60	$330.00
Chris Kazantzis	10/24/2026	Apple Tree Life	Sales Process	Reviewed Rigmora LOI	1.30	$715.00

		Sciences				
Chris Kazantzis	10/25/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski discussing questions for B. Riley	0.10	$55.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Sales Process	Met with B Riley to discuss sale process	0.40	$220.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Internal call recapping meeting with Briley on LOIs	0.30	$165.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed claims by debtor entity with B. Galfus and M. Whalen	1.40	$770.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Sales Process	Finalized LOI summary with B. Galfus after incorporating claims by Debtor	1.60	$880.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal call reviewing analysis of LOIs	1.80	$990.00
Chris Kazantzis	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski and J. Nahas reviewing additional updates to bids deck	0.70	$385.00
Chris Kazantzis	10/28/2026	Apple Tree Life Sciences	Claims Analysis	Call with C. Podesfinski discussing claims and response to counsel	0.40	$220.00
Chris Kazantzis	10/28/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed scheduled and filed claims and edited claims analysis excel	1.60	$880.00
Chris Kazantzis	10/29/2026	Apple Tree Life Sciences	Business Analysis	Reviewed cash position excel sent by Debtor	2.40	$1,320.00
Chris Kazantzis	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Call with C. Podesfinski reviewing B. Riley claims analysis	0.20	$110.00
Chris Kazantzis	10/29/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Met with B. Riley to discuss claims analysis	0.50	$275.00
Chris Kazantzis	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed B Riley Claims Analysis	1.20	$660.00
Totals For Chris Kazantzis					**25.70**	**$14,135.00**

Christopher Podesfinski	10/01/2026	Apple Tree Life Sciences	Sales Process	Begin due diligence into new parties added to marketing process	4.20	$3,150.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Business Analysis	Review final order regarding secured loans to portcos (D.I. 206); check against newly added notes to data room	0.80	$600.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Case Administration	Search of data room for files related to Replicate IP	1.20	$900.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Investigations	Review diligence responses across Deep Apple, Marlinspike, and Apertor	1.00	$750.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Business Analysis	Review October 2026 Nereid update	0.40	$300.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Business Analysis	Continued diligence of updated Braeburn master model	3.20	$2,400.00
Christopher Podesfinski	10/02/2026	Apple Tree Life Sciences	Business Analysis	Call with J. Nahas about status of review of files added over last months, current status of workstreams, new parties to process, etc.	0.90	$675.00
Christopher Podesfinski	10/03/2026	Apple Tree Life Sciences	Retention and Fee Applications	Begin creation of fee application exhibits (September)	0.20	$150.00
Christopher Podesfinski	10/05/2026	Apple Tree Life Sciences	Business Analysis	Review 10/5 Aethon presentation	1.00	$750.00
Christopher Podesfinski	10/05/2026	Apple Tree Life Sciences	Sales Process	Diligence around 25 new parties to marketing process	3.60	$2,700.00
Christopher Podesfinski	10/06/2026	Apple Tree Life Sciences	Sales Process	Review and research Aulos due diligence questions/responses	0.90	$675.00
Christopher Podesfinski	10/06/2026	Apple Tree Life Sciences	Sales Process	Review competitive landscape slide added to data room	0.10	$75.00
Christopher Podesfinski	10/06/2026	Apple Tree Life Sciences	Sales Process	Diligence another ~20 parties new to marketing process	2.70	$2,025.00
Christopher Podesfinski	10/07/2026	Apple Tree Life Sciences	Business Analysis	Analyze Red Queen budget (July 2026) with supporting schedules	2.40	$1,800.00

Christopher Podesfinski	10/07/2026	Apple Tree Life Sciences	Business Analysis	Review 10/5 deck on Red Queen; including background on precedent transaction mentioned	2.10	$1,575.00
Christopher Podesfinski	10/07/2026	Apple Tree Life Sciences	Retention and Fee Applications	Finalize exhibits and fee application (September)	1.20	$900.00
Christopher Podesfinski	10/08/2026	Apple Tree Life Sciences	Sales Process	Review marketing update and B. Riley commentary; including background on 8 new parties under NDA	1.60	$1,200.00
Christopher Podesfinski	10/09/2026	Apple Tree Life Sciences	Business Analysis	Read KPMG auditors report for Ascidian (FY 2025)	2.60	$1,950.00
Christopher Podesfinski	10/09/2026	Apple Tree Life Sciences	Business Analysis	Review Q3 2026 Evercrisp update	1.10	$825.00
Christopher Podesfinski	10/09/2026	Apple Tree Life Sciences	Business Analysis	Review various other new additions to data room	0.40	$300.00
Christopher Podesfinski	10/11/2026	Apple Tree Life Sciences	Sales Process	Continue diligencing new parties to process	2.20	$1,650.00
Christopher Podesfinski	10/12/2026	Apple Tree Life Sciences	Sales Process	Create PEO marketing/sale process update for counsel	2.90	$2,175.00
Christopher Podesfinski	10/13/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Read counsel's case updates to Committee members	0.10	$75.00
Christopher Podesfinski	10/13/2026	Apple Tree Life Sciences	Case Administration	Review draft UCC objection to officeholder clarification motion	0.20	$150.00
Christopher Podesfinski	10/13/2026	Apple Tree Life Sciences	Business Analysis	Review objection by portcos to officeholder motion (D.I. 1209)	0.20	$150.00
Christopher Podesfinski	10/13/2026	Apple Tree Life Sciences	Business Analysis	Additional analysis/diligence of Braeburn model	2.20	$1,650.00
Christopher Podesfinski	10/13/2026	Apple Tree Life Sciences	Sales Process	Call with J. Nahas prepping for Thursday sales call; reviewing parties in data room, questions to ask, etc.	1.20	$900.00
Christopher Podesfinski	10/15/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing marking process updates/interested parties	0.50	$375.00

Christopher Podesfinski	10/15/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Prep for call with B. Riley (finalize question list, review previous call notes, etc.)	0.50	$375.00
Christopher Podesfinski	10/15/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review limited objection to QE professional fees (D.I. 1217) and related fee application time detail	0.40	$300.00
Christopher Podesfinski	10/15/2026	Apple Tree Life Sciences	Business Analysis	Review of Apertor (.6) and Initial (.5) presentations	1.10	$825.00
Christopher Podesfinski	10/16/2026	Apple Tree Life Sciences	Sales Process	Review B. Riley marketing update	0.40	$300.00
Christopher Podesfinski	10/16/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian presentation (10/15)	0.70	$525.00
Christopher Podesfinski	10/16/2026	Apple Tree Life Sciences	Sales Process	Creating marketing update deck for counsel	2.40	$1,800.00
Christopher Podesfinski	10/16/2026	Apple Tree Life Sciences	Business Analysis	Read new docs related to Initial (diligence questions from interested party; investor agreement)	0.40	$300.00
Christopher Podesfinski	10/17/2026	Apple Tree Life Sciences	Business Analysis	Review Marengo October 2026 presentation	0.50	$375.00
Christopher Podesfinski	10/17/2026	Apple Tree Life Sciences	Business Analysis	Review confidential presentation for Ascidian	0.90	$675.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Business Analysis	Review of Aethon program materials	1.60	$1,200.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Read 10/19 Committee update email and attachments regarding updates to clarification motion	0.40	$300.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Attend call with Potter and Cole Schotz discussing case updates and clarification motion	0.50	$375.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Case Administration	Download of new files from the data room	0.60	$450.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Virtually attend hearing (will be continued in November)	0.10	$75.00

Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review Orrick retention letter for fund debtor	0.20	$150.00
Christopher Podesfinski	10/19/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian development and timelines	0.10	$75.00
Christopher Podesfinski	10/20/2026	Apple Tree Life Sciences	Business Analysis	Review IP/milestone update from Marlinspike	0.10	$75.00
Christopher Podesfinski	10/20/2026	Apple Tree Life Sciences	Business Analysis	Review of various new data room files (financial statements, AETX patents portfolio, DA October presentation, etc.)	3.30	$2,475.00
Christopher Podesfinski	10/20/2026	Apple Tree Life Sciences	Sales Process	Continued diligence into new parties into data room / process	4.30	$3,225.00
Christopher Podesfinski	10/21/2026	Apple Tree Life Sciences	Business Analysis	Continued review of new files in data room mostly related to Deep Apple, but also diligence responses from Evercrisp/Initial	3.10	$2,325.00
Christopher Podesfinski	10/21/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian org chart (as of mid October) (.1); research background on senior personnel (.4)	0.50	$375.00
Christopher Podesfinski	10/22/2026	Apple Tree Life Sciences	Business Analysis	Review of new files across Aulos, Galvanize, Nereid and Marengo	2.90	$2,175.00
Christopher Podesfinski	10/22/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley ahead of bid deadline	0.30	$225.00
Christopher Podesfinski	10/22/2026	Apple Tree Life Sciences	Business Analysis	Review/comments on WIP case to date MOR presentation	2.40	$1,800.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with J. Nahas regarding bids received to date	0.80	$600.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email to counsel regarding bid received; takeaways from B. Riley call	0.10	$75.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Sales Process	Re-review of initial term sheets/bids in light of bid deadline	2.40	$1,800.00

Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Business Analysis	Review YTD financials for Ascidian	0.20	$150.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Sales Process	Initial read of Rigmora's 10/23 DIP/term sheet	1.90	$1,425.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with J. Nahas discussing bidder interest, Rigmora term sheet, deliverables	1.10	$825.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email to B. Riley regarding bids	0.10	$75.00
Christopher Podesfinski	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review G. Lipson email regarding issues with Rigmora plan	0.20	$150.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review high level bid summary email from B. Riley	0.20	$150.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with J. Nahas regarding Rigmora term sheet and creditor impairment	0.30	$225.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Business Analysis	Review Dundon chart on missing bids (.2); email to counsel regarding missing bids (.1)	0.30	$225.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	DIP, Exit and Other Financing	Re-review of exit financing procedures (.4); internal email regarding qualified bids (.2)	0.60	$450.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Business Analysis	Research into Rigmora original reserve pricing	1.20	$900.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Sales Process	Call with J. Nahas regarding reserve prices versus bids	0.30	$225.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Kazantzis regarding bid summary deliverable	0.20	$150.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Business Analysis	Review historical emails/notes regarding Q1 2026 valuation	0.70	$525.00

Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Sales Process	Internal call discussing/understanding bids/structures/implications	2.80	$2,100.00
Christopher Podesfinski	10/24/2026	Apple Tree Life Sciences	Sales Process	Initial review all LOIs received	3.50	$2,625.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Retention and Fee Applications	Continue third interim fee application	2.30	$1,725.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Retention and Fee Applications	Transform September fee application into October fee application	1.10	$825.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Retention and Fee Applications	Incremental updates to third interim fee application to account for voluntary fee reduction.	0.10	$75.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Sales Process	Call with J. Nahas putting together question list for B,. Riley	1.40	$1,050.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Sales Process	Continuing to review bidders and their bids	2.30	$1,725.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Sales Process	Call with C. Kazantzis discussing bid questions	0.10	$75.00
Christopher Podesfinski	10/25/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review counsel's communication to Committee members about bids received	0.20	$150.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Re-review of Dundon claims analysis, secured notes outstanding, and claims register	1.80	$1,350.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Call with C. Kazantzis and J. Nahas discussing deck updates regarding claims	0.70	$525.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Call with J. Nahas discussing claims pools by portco	0.80	$600.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Review additional bid received today	1.00	$750.00

Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing bids	0.40	$300.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Prep ahead of call with B. Riley regarding bids	0.40	$300.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal call discussing takeaways from B. Riley call on bids	0.30	$225.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Review B. Riley detailed bid summary materials	2.60	$1,950.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Call with J. Nahas discussing bid deliverable	0.20	$150.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email response to counsel regarding Dundon bid analysis	0.10	$75.00
Christopher Podesfinski	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal team call reviewing/updating draft of Dundon bid analysis	1.80	$1,350.00
Christopher Podesfinski	10/27/2026	Apple Tree Life Sciences	Sales Process	Review updated draft of B. Riley materials	0.80	$600.00
Christopher Podesfinski	10/27/2026	Apple Tree Life Sciences	Sales Process	Review final draft of Dundon bid analysis before sending to counsel/UCC	0.60	$450.00
Christopher Podesfinski	10/27/2026	Apple Tree Life Sciences	Sales Process	Review new bid analysis slides created overnight	1.20	$900.00
Christopher Podesfinski	10/27/2026	Apple Tree Life Sciences	Claims Analysis	Call with B. Galfus making updates to claims by portco charts	0.30	$225.00
Christopher Podesfinski	10/27/2026	Apple Tree Life Sciences	Business Analysis	Review three filed monthly operating reports for September (Marlinspike, Apertor, ATP III) and compare to previous filings	1.70	$1,275.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review case update email sent by counsel to Committee members	0.10	$75.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review motion to disqualify Quinn Emanuel	0.70	$525.00

Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Virtually attend hearing	0.40	$300.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review and provide comments on communication to Committee members regarding bids post Dundon analysis	0.60	$450.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review fee reviewer reports across all professionals (excluding Dundon)	1.00	$750.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Claims Analysis	Call with Chris Kazantzis discussing claims pool sizing post counsel email with questions	0.40	$300.00
Christopher Podesfinski	10/28/2026	Apple Tree Life Sciences	Claims Analysis	Review of "low hanging fruit" possible objections for filed POCs	3.80	$2,850.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Review further updated B. Riley claims analysis regarding possible objections/reductions/ next steps	1.30	$975.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Discuss B. Riley provided claims analysis with C. Kazantzis	0.20	$150.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Call with B. Galfus discussing claims related to rejection damages/equipment leases	0.70	$525.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Review of B. Riley claims analysis	3.40	$2,550.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Prep ahead of meeting with Debtors and CAO on claims analysis	0.50	$375.00
Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing their/Dundon claims analysis; possible issues with certain claims	0.50	$375.00

Christopher Podesfinski	10/29/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email to counsel regarding takeaways of B. Riley call and other claims related issues	0.30	$225.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review further updates from counsel regarding plan support agreement	0.20	$150.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Business Analysis	Analysis of cash position assessment (assumptions, employees retained, budgets, etc.)	3.60	$2,700.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review email from counsel regarding Committee's position on current plan	0.10	$75.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Create open questions list ahead of B. Riley claims call	0.30	$225.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley & A&M discussing updates to claims analysis	0.30	$225.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Sales Process	Review further updated B. Riley bid comparison materials and underlying updated bids	1.20	$900.00
Christopher Podesfinski	10/30/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email to counsel explaining. B. Riley claims analysis / next steps	0.30	$225.00
Christopher Podesfinski	10/31/2026	Apple Tree Life Sciences	Claims Analysis	Update Dundon claims analysis to match B. Riley analysis	2.30	$1,725.00
Christopher Podesfinski	10/31/2026	Apple Tree Life Sciences	Sales Process	Review updated bid for a portco and compare against initial	0.80	$600.00
Christopher Podesfinski	10/31/2026	Apple Tree Life Sciences	DIP, Exit and Other Financing	Review filed plan term sheet/DIP agreement	2.90	$2,175.00
Christopher Podesfinski	10/31/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review quarterly report on OCP fees (D.I. 1279)	0.10	$75.00
Totals For Christopher Podesfinski					**133.90**	**$100,425.00**

Gary Lipson	10/01/2026	Apple Tree Life Sciences	Business Analysis	Review and analyze portco valuation and transaction considerations, including IP/licensing, financing, and change-of-control issues; identify additional diligence items and update the valuation analysis.	1.90	$2,128.00
Gary Lipson	10/15/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Participated in call with J. Brown, I. Belov, C. Podesfinski, et al., regarding ATLS portco marketing progress, bidder interest, sponsor financing, October 23 bid deadline, and Cayman Officeholder governance issues.	0.50	$560.00
Gary Lipson	10/15/2026	Apple Tree Life Sciences	Business Analysis	Reviewed recent ATLS data room materials and marketing developments; assessed buyer specific IP and licensing considerations, identified outstanding diligence issues, and prioritized further review in advance of the October 23 bid deadline.	0.50	$560.00
Gary Lipson	10/18/2026	Apple Tree Life Sciences	Business Analysis	Reviewed recent ATLS data room materials and marketing developments, focusing on IP and licensing considerations affecting portco asset values, transaction structures, and potential creditor recoveries.	0.70	$784.00

Gary Lipson	10/19/2026	Apple Tree Life Sciences	Business Analysis	Reviewed governance motion, PortCo Debtors' objection and revised proposed order, focusing on potential implications for IP asset preservation, management continuity and the pending sale process.	0.40	$448.00
Gary Lipson	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Participated in ATP Debtors and UCC coordination call with K. Good, J. Dougherty, J. Nahas, et al., regarding resolution of governance objections, committee consultation rights, PortCo transaction issues, October 23 bid deadline, and case budget considerations.	0.50	$560.00
Gary Lipson	10/21/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Aethon, Deep Apple and Nereid IP and licensing matters, including patent preservation, invention ownership, and preclinical development updates, assessing implications for PortCo asset values and the pending sale process.	0.90	$1,008.00
Gary Lipson	10/23/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Rigmora's proposed restructuring plan and IP sale provisions, focusing on PortCo asset ownership, licensing implications and preservation of IP value for the debtor estates; provided comments internally regarding potential IP issues.	0.60	$672.00

Gary Lipson	10/24/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Carlyle/Oaktree portfolio acquisition proposal, focusing on IP ownership, research agreement rights, licensing implications and transferability considerations.	0.30	$336.00
Gary Lipson	10/26/2026	Apple Tree Life Sciences	Business Analysis	Reviewed updated ATLS term sheet comparison and creditor claims analysis, including Portco bid economics, IP considerations, and implications for creditor recoveries; provided comments regarding presentation accuracy.	0.30	$336.00
Gary Lipson	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Attended conference call with P. Mandarino, J. Nahas, C. Podesfinski, et al., regarding competing bids, Rigmora restructuring proposal, portfolio-company treatment, creditor recoveries, and sale process developments.	0.40	$448.00
Gary Lipson	10/27/2026	Apple Tree Life Sciences	Business Analysis	Continued review of updated ATLS term sheet comparison and creditor claims analysis.	0.30	$336.00
Gary Lipson	10/28/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Monitored ATLS bankruptcy court status hearing, focusing on potential implications of counsel disqualification and PortCo representation disputes for IP asset sales, ownership rights, and transaction timing. (partial)	0.20	$224.00
Totals For Gary Lipson					**7.50**	**$8,400.00**
Joshua Nahas	10/01/2026	Apple Tree Life	Business Analysis	Continued background work on new parties in	3.00	$3,360.00

		Sciences		data room		
Joshua Nahas	10/02/2026	Apple Tree Life Sciences	Investigations	Review responses to diligence questions across 3 portcos	1.20	$1,344.00
Joshua Nahas	10/02/2026	Apple Tree Life Sciences	Business Analysis	Review Nereid overview (October)	0.20	$224.00
Joshua Nahas	10/02/2026	Apple Tree Life Sciences	Business Analysis	Review final order regarding secured loans to portcos	0.10	$112.00
Joshua Nahas	10/02/2026	Apple Tree Life Sciences	Business Analysis	Call with C. Podesfinski discussing newly added data room files; workstreams in short term	0.90	$1,008.00
Joshua Nahas	10/02/2026	Apple Tree Life Sciences	Sales Process	Continued research into new parties to marketing process	2.30	$2,576.00
Joshua Nahas	10/03/2026	Apple Tree Life Sciences	Business Analysis	Orientation to updated Braeburn model; review inputs, support tabs	2.60	$2,912.00
Joshua Nahas	10/05/2026	Apple Tree Life Sciences	Business Analysis	Read through 10/5 presentation for portco Aethon	0.80	$896.00
Joshua Nahas	10/07/2026	Apple Tree Life Sciences	Retention and Fee Applications	Review and approve 8th fee application	0.40	$448.00
Joshua Nahas	10/07/2026	Apple Tree Life Sciences	Business Analysis	Read through Aulos DD questions and responses	0.70	$784.00
Joshua Nahas	10/07/2026	Apple Tree Life Sciences	Business Analysis	Review October presentation (Red Queen)	1.60	$1,792.00
Joshua Nahas	10/07/2026	Apple Tree Life Sciences	Business Analysis	Review Red Queen go forward budget/cash needs/expenses	2.00	$2,240.00
Joshua Nahas	10/08/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Aethon presentation, poster, and article	1.10	$1,232.00
Joshua Nahas	10/08/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Evercrisp corporate deck	0.60	$672.00
Joshua Nahas	10/08/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Ascidian FY 2025 audited financials	2.20	$2,464.00
Joshua Nahas	10/08/2026	Apple Tree Life Sciences	Sales Process	Review latest B. Riley marketing update	0.90	$1,008.00
Joshua Nahas	10/12/2026	Apple Tree Life	Sales Process	Review and approve PEO sale deck	0.50	$560.00

		Sciences				
Joshua Nahas	10/12/2026	Apple Tree Life Sciences	Sales Process	Continued research on new parties to process, specifically new executed NDAs	3.00	$3,360.00
Joshua Nahas	10/13/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Read counsel's update email to Committee	0.10	$112.00
Joshua Nahas	10/13/2026	Apple Tree Life Sciences	Case Administration	Review draft UCC objection to officeholder clarification motion	0.20	$224.00
Joshua Nahas	10/13/2026	Apple Tree Life Sciences	Case Administration	Review objection by portcos to officeholder motion	0.20	$224.00
Joshua Nahas	10/13/2026	Apple Tree Life Sciences	Sales Process	Call with C. Podesfinski prepping for Thursday call with B. Riley	1.20	$1,344.00
Joshua Nahas	10/15/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Apertor and Initial overview presentations	1.10	$1,232.00
Joshua Nahas	10/15/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley to discuss sale process updates	0.50	$560.00
Joshua Nahas	10/15/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review objection to Debtors' counsel fees (Dkt. 1217).	0.20	$224.00
Joshua Nahas	10/16/2026	Apple Tree Life Sciences	Business Analysis	Review Initial's Q3 presentation	0.70	$784.00
Joshua Nahas	10/16/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian October 2026 corporate overview	0.80	$896.00
Joshua Nahas	10/16/2026	Apple Tree Life Sciences	Sales Process	Review and approve PEO marketing deck	0.30	$336.00
Joshua Nahas	10/16/2026	Apple Tree Life Sciences	Business Analysis	Review diligence questions sent to Initial	0.20	$224.00
Joshua Nahas	10/16/2026	Apple Tree Life Sciences	Sales Process	Review investing history/aum/general background on additional new parties in process on marketing update/discussed on B. Riley call yesterday	4.40	$4,928.00

Joshua Nahas	10/17/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Marengo October overview presentation	0.70	$784.00
Joshua Nahas	10/17/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Braeburn investor rights agreement	0.90	$1,008.00
Joshua Nahas	10/17/2026	Apple Tree Life Sciences	Business Analysis	Review updated materials from Ascidian	1.00	$1,120.00
Joshua Nahas	10/17/2026	Apple Tree Life Sciences	Sales Process	Additional background research on Rigmora ahead of initial bid deadline	3.60	$4,032.00
Joshua Nahas	10/19/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian update	0.10	$112.00
Joshua Nahas	10/19/2026	Apple Tree Life Sciences	Business Analysis	Review additional materials related to Aethon	1.10	$1,232.00
Joshua Nahas	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Read counsel's email regarding clarification motion and general case updates	0.50	$560.00
Joshua Nahas	10/19/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Attend call with Potter/UCC counsel on general updates/clarification motion	0.50	$560.00
Joshua Nahas	10/19/2026	Apple Tree Life Sciences	Other Professionals' Retention and Fee Applications	Review Orrick retention letter	0.10	$112.00
Joshua Nahas	10/20/2026	Apple Tree Life Sciences	Business Analysis	Review Marlinspike update	0.10	$112.00
Joshua Nahas	10/21/2026	Apple Tree Life Sciences	Business Analysis	Catchup on two days of new materials in data room related to Deep Apple, Initial Thera, Evercrisp	3.60	$4,032.00
Joshua Nahas	10/22/2026	Apple Tree Life Sciences	Business Analysis	Review write up on clinical therapies and issues in other trials	1.40	$1,568.00
Joshua Nahas	10/22/2026	Apple Tree Life Sciences	Sales Process	Continue due diligence into new parties signing NDAs/reviewing materials	3.50	$3,920.00
Joshua Nahas	10/22/2026	Apple Tree Life Sciences	Business Analysis	Review "AI" angle to Deep Apple mentioned by B. Riley/C. Podesfinski	1.50	$1,680.00

Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Business Analysis	Review Ascidian financials	0.20	$224.00
Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Sales Process	Review of Rigmora's bid package	2.50	$2,800.00
Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Business Analysis	Provide comments on draft MOR presentation	1.20	$1,344.00
Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski discussing bid summary needed; possible bidders; Rigmora bid	1.10	$1,232.00
Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Business Analysis	Review files related to Galvanize, Nereid, Marengo, etc. escalated by B. Galfus	2.20	$2,464.00
Joshua Nahas	10/23/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski discussing bids	0.80	$896.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski discussing Rigmora plan	0.30	$336.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Email to counsel regarding messaging for bids received to Committee members	0.30	$336.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Sales Process	Review Dundon analysis of Rigmora reserve pricing by pool; check against qualifying bid requirements	1.40	$1,568.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Sales Process	Review three bids received yesterday	2.70	$3,024.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Sales Process	Research into bidder for Ascidian, their capitalization, etc.	2.30	$2,576.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with C. Podesfinski regarding reserve price/valuation	0.30	$336.00
Joshua Nahas	10/24/2026	Apple Tree Life Sciences	Sales Process	Internal call discussing bids received	2.80	$3,136.00
Joshua Nahas	10/25/2026	Apple Tree Life Sciences	Claims Analysis	Review of high dollar claims / KCC claims register	3.60	$4,032.00

Joshua Nahas	10/25/2026	Apple Tree Life Sciences	Sales Process	Call with C.Podesfinski re: questions for B. Riley	1.40	$1,568.00
Joshua Nahas	10/25/2026	Apple Tree Life Sciences	Sales Process	Continuation of review of bidders/bids	3.30	$3,696.00
Joshua Nahas	10/25/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Review email to UCC from counsel on bids	0.10	$112.00
Joshua Nahas	10/25/2026	Apple Tree Life Sciences	Sales Process	Review Q1 2026 valuation materials in light of bids received	3.20	$3,584.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Call with C. Podesfinski and C. Kazantzis discussing claims / bid analysis deck changes	0.70	$784.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Additional review/comments on next turn of Dundon bid analysis materials	2.20	$2,464.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Call with C. Podesfinski discussing claims pool	0.80	$896.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Review new bid from sponsor backed strategic	0.80	$896.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing bids	0.40	$448.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal call discussing B. Riley call and next steps on deliverables	0.30	$336.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Review B. Riley bid summary deck and compare to underlying bids	2.90	$3,248.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Call with C. Podesfinski discussing Dundon bid summary analysis	0.20	$224.00
Joshua Nahas	10/26/2026	Apple Tree Life Sciences	Sales Process	Internal call incrementally updating Dundon bid analysis	1.80	$2,016.00
Joshua Nahas	10/27/2026	Apple Tree Life Sciences	Business Analysis	Reviewed and approved final draft of bid overview presentation	1.70	$1,904.00
Joshua Nahas	10/27/2026	Apple Tree Life Sciences	Business Analysis	Diligence strategic and sponsor who submitted latest bid	2.50	$2,800.00

Joshua Nahas	10/27/2026	Apple Tree Life Sciences	Business Analysis	Reviewed latest version of B Riley term sheet materials	1.00	$1,120.00
Joshua Nahas	10/27/2026	Apple Tree Life Sciences	Sales Process	Review/comments on deck updates, re: bid + claims analysis	1.40	$1,568.00
Joshua Nahas	10/28/2026	Apple Tree Life Sciences	Hearing, Mediation and Arbitration Preparation	Virtually attend hearing on status updates	0.40	$448.00
Joshua Nahas	10/28/2026	Apple Tree Life Sciences	Business Analysis	Reviewed Apertor and Marlinspike MORs that filed 10/27	2.00	$2,240.00
Joshua Nahas	10/28/2026	Apple Tree Life Sciences	Business Analysis	Reviewed and changed language for communication to counsel regarding filed claims at sale portcos	0.40	$448.00
Joshua Nahas	10/28/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed claims register for potentially objectionable POCs	2.30	$2,576.00
Joshua Nahas	10/29/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed B. Riley claims analysis with supporting schedules (including comparison to Dundon analysis)	4.00	$4,480.00
Joshua Nahas	10/29/2026	Apple Tree Life Sciences	Committee Member/Professional Meetings & Communications	Call with B. Riley discussing claims analysis and comparison between Dundon and BR analysis	0.50	$560.00
Joshua Nahas	10/30/2026	Apple Tree Life Sciences	Sales Process	Review of updated LOI materials from B Riley and related revised bids	1.00	$1,120.00
Joshua Nahas	10/30/2026	Apple Tree Life Sciences	Business Analysis	Reviewed October 20 cash position assessment with supporting schedules	3.40	$3,808.00
Totals For Joshua Nahas					**113.00**	**$126,560.00**
Michael Whalen	10/26/2026	Apple Tree Life Sciences	Claims Analysis	Reviewed claims by Debtor with B. Galfus and C. Kazantzis	1.40	$1,211.00
Totals For Michael Whalen					**1.40**	**$1,211.00**
			Total		**326.50**	**$268,281.00**